bioRxiv Science⌕ Search

Biology subjects

Greiff, L.

Publications and source records attributed to Greiff, L..

2 recordsLinked to original sources

Differentiation of THP-1 Cells in 3D Cancer-Stromal Tissue by Collagen Microfiber for Replicating of Tumor Microenvironment

Abstract textIn three-dimensional (3D) cancer tissue models, the low solubility of type I collagen (Col I) is a limitation in reproducing cancer tissue with high collagen density. we previously reported a "sedimentation culture method" using collagen microfibers (CMF) homogenized Col I powder. This 3D cancer tissue model is expected to reproduce tumor microenvironment comparable to that in tumors bearing mice owing to its high collagen density. However, this 3D cancer tissue model including immune cells such as macrophages has not been reported. In this study, we fabricated a 3D culture system including normal human dermal fibroblasts, human umbilical vein endothelial cells, and cancer cells human monocytes cell line; THP-1 cells by sedimentation culture using CMF. 3D cancer tissue models co-cultured with human colorectal cancer cells for 5 days increased the expression levels of CD14 and CD206, markers of macrophages and M2 macrophages, in THP-1 cells, suggesting differentiation induction toward macrophages and polarization toward M2-like macrophages. We could also demonstrate the applicability of drug efficacy evaluation systems by evaluating the cytotoxicity of poly(vinyl alcohol)-ursodeoxycholic acid15 that induce cell death in response to weak acidic tumor microenvironment in 3D cancer tissue models with macrophages. This 3D cancer tissue models with macrophages are expected to be applied as tools for evaluating the efficacy of cancer therapeutic molecules and for understanding in detail the behavior of immune cells within the tumor microenvironment.

bioengineering↗

A cancer immunotherapy modality based on dendritic cell reprogramming in vivo

Immunotherapy leads to long-term survival of cancer patients, yet generalized success has been hampered by insufficient antigen presentation and exclusion of immunogenic cells from the tumor microenvironment. Here, we developed an approach to reprogram tumor cells in vivo by adenoviral delivery of the transcription factors PU.1, IRF8, and BATF3, which enabled them to present antigens as type 1 conventional dendritic cells. Reprogrammed tumor cells remodeled their tumor microenvironment, recruited, and expanded polyclonal cytotoxic T cells, induced complete tumor regressions, and established long-term systemic immunity in different mouse melanoma models. In human tumor spheroids and xenografts, reprogramming to immunogenic dendritic-like cells progressed independently of immunosuppression, which usually limits immunotherapy. Our study paves the way for first-in-human trials and other applications of immune cell reprogramming in vivo. One-Sentence SummaryReprogramming of tumor cells to cDC1-like cells in vivo elicits systemic and long-term antitumor immunity.

immunology↗